3 research outputs found
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update
Blood graft and outcome after autologous stem cell transplantation in patients with primary central nervous system lymphoma
Abstract
Background: Autologous stem cell transplantation (auto-SCT) is a treatment option for patients with primary central nervous system lymphoma (PCNSL).
Methods: In this prospective multicenter study, the effects of blood graft cellular content on hematologic recovery and outcome were analyzed in 17 PCNSL patients receiving auto-SCT upfront.
Results: The infused viable CD34âș cell count > 1.7 Ă 10â¶/kg correlated with more rapid platelet engraftment (10 vs. 31 days, P = 0.027) and with early neutrophil recovery (day + 15) (5.4 vs. 1.6 Ă 10âč/L, P = 0.047). A higher number of total collected CD34âș cells > 3.3 Ă 106/kg infused predicted worse 5-year progression-free survival (PFS) (33% vs. 100%, P = 0.028). In addition, CD3âșCD8âș T cells > 78 Ă 10â¶/kg in the infused graft impacted negatively on the 5-year PFS (0% vs. 88%, P = 0.016).
Conclusions: The cellular composition of infused graft seems to impact on the hematologic recovery and PFS post-transplant. Further studies are needed to verify the optimal autograft cellular content in PCNSL